Nerve-Sparing Surgery for Cervical Cancer May Protect Sex Life

This article originally appeared here.
Share this content:
Nerve-Sparing Surgery for Cervical CA May Protect Sex Life
Nerve-Sparing Surgery for Cervical CA May Protect Sex Life

(HealthDay News) -- Nerve-sparing (NS) laparoscopic radical hysterectomy (LRH) impairs sexual function less than conventional LRH in cervical cancer patients, according to a study published in the December issue of the Journal of Sexual Medicine.

Giorgio Bogani, M.D., from the University of Insubria in Varese, Italy, and colleagues evaluated sexually active cervical cancer patients undergoing type C (class III) LRH (2004 to 2013). The authors sought to determine the impact of NS procedures on preoperative versus postoperative sexual function.

The researchers found that, of the 40 patients undergoing radical hysterectomy (20 conventional LRH versus 20 NS-LRH), there were no differences in preoperative Female Sexual Function Index (FSFI) scores (P > 0.05). While postoperative FSFI scores were worse in both groups (P < 0.001), patients undergoing NS-LRH had higher postoperative FSFI scores than patients undergoing conventional LRH (21.3 versus 14.2; P = 0.04). Specific postoperative domain scores showed that desire, arousal, orgasm, and pain scores were similar between groups (P > 0.05), while patients undergoing NS-LRH experienced higher lubrication (3.4 versus 1.7; P = 0.02) and satisfaction (4.6 versus 2.8; P = 0.004) scores, compared to patients undergoing conventional LRH. Survival outcomes were similar between the groups.

"The NS approach impairs sexual function less, minimizing the effects of radical surgery," the authors write.

Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions

Sign up for myCME e-newsletters

More in Home

FDA Approves Palynziq for Phenylketonuria

FDA Approves Palynziq for Phenylketonuria

Drug is a novel enzyme therapy for adult patients with PKU with uncontrolled blood Phe concentrations

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in proportion of adults recommended for treatment; estimated decrease in CVD events, deaths